ReviewAntibiotics (Basel, Switzerland)2025
Novel Antibacterial Approaches and Therapeutic Strategies.
Review in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global trends in carbapenem-resistant gram-negative bacteria research (2020-2025): a bibliometric analysis and systematic review.Frontiers in cellular and infection microbiology · 2025Pooled it
- Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025).Medicinal research reviews · 2026Review
- Circular-by-Design Zwitterionic Polyglycerol-Polyoxazoline-Lysine Pseudodendrimers as Multifunctional Antibacterial and Anticancer Drug Delivery Platforms.Biomacromolecules · 2026Article
- Article
- Prokaryotic Expression and Preliminary Application of Lys40, an Endolysin from Broad-Host-Range Salmonella enterica Phage SP_4.Current microbiology · 2026Article
- Antibody-Antibiotic Conjugates: Mechanisms, Clinical Progress, and Next-Generation Strategies Against Multidrug-Resistant Bacterial Infections.MicrobiologyOpen · 2026Review
- Anti-infective compounds forSustainable microbiology · 2026Review
- The WHO priority list of antibiotic-resistant bacteria: challenges and opportunities for next-generation antimicrobial development.Frontiers in pharmacology · 2026Review
- The Evolving Triad of Carbapenem Resistance: Emergence of Dominant CRPA, Persistent CRAB, and Rebounding CRKP in a Chinese Regional Hospital (2020-2024).Infection and drug resistance · 2026Article
- Er:YAG Laser Energy Optimization for Reducing Single-Species Microbial Growth on Agar Surfaces In Vitro.Pathogens (Basel, Switzerland) · 2025Article
- Photodynamic Microbial Defense of Cotton Fabric with 4-Amino-1,8-naphthalimide-Labeled PAMAM Dendrimer.Materials (Basel, Switzerland) · 2025Article
- Essential Oils as Antimicrobial Agents Against WHO Priority Bacterial Pathogens: A Strategic Review of In Vitro Clinical Efficacy, Innovations and Research Gaps.Antibiotics (Basel, Switzerland) · 2025Review
- Article
- Review
- The Photodynamic Antibacterial Potential of New Tetracationic Zinc(II) Phthalocyanines Bearing 4-((Diethylmethylammonium)methyl)phenoxy Substituents.International journal of molecular sciences · 2025Article
- Exploring the dynamic relationship between antimicrobial resistance, virulence fitness, and host responses in Listeria monocytogenes infections.Scientific reports · 2025Article
- Research progress on bacterial outer membrane vesicles in antibiotic resistance and clinical anti-infective therapy.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increase in multidrug-resistant organisms worldwide is a major public health threat driven by antibiotic overuse, horizontal gene transfer (HGT), environmental drivers, and deficient infection control in hospitals. In this article, we discuss these factors and summarize the new drugs and treatment strategies suggested to combat the increasing challenges of multidrug-resistant (MDR) bacteria. New treatments recently developed involve targeting key processes involved in bacterial growth, such as riboswitches and proteolysis, and combination therapies to improve efficacy and minimize adverse effects. It also tackles the challenges of the Gram-negative bacterial outer membrane, stressing that novel strategies are needed to evade permeability barriers, efflux pumps, and resistance mechanisms. Other approaches, including phage therapy, AMPs, and AI in drug discovery, are also discussed as potential alternatives. Finally, this review points out the urgency for continued research and development (R&D), industry-academic partnerships, and financial engines to ensure that MDR microbes do not exceed the value of antibacterial therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.